Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

What Factors Guide CLL Patients’ Treatment Choices

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.

CLL Society’s Robyn Brumble, RN, and Brian Koffman, MDCM, were authors in the recent publication in the peer-reviewed, free-access medical journal Oncology Future of the Experiment: Patient Preferences for Chronic Lymphocytic Leukemia Treatments: a discrete-choice Experiment.

Our research found that improving progression-free survival (PFS) and confirming results with testing for measurable (minimal) residual disease (MRD) were the most critical factors for those chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) when choosing a therapy.

A discrete choice experiment works by forcing selection between given choices. The full article provides further explanation and more findings.

CLL Society is grateful to the patients and care partners who participated in the study and is proud to continue producing necessary research that helps understand and explain the patient’s journey.